---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-229153"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-05-18T21:20:47+00:00"
generated_at: "2026-05-18T21:25:17.802120+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio signs exclusive U.S. supply agreement with Japan BCG Laboratory for Tokyo strain of BCG

## Summary
- Agreement grants ImmunityBio exclusive U.S. rights to develop and commercialize Tokyo-172 BCG for 10 years after FDA approval.
- Positive Phase III SWOG S1602 trial demonstrated non-inferiority of Tokyo strain vs TICE BCG in high-grade NMIBC (HR 0.82; 95.8% CI 0.63–1.08).
- ImmunityBio plans to engage FDA for BLA submission as sole applicant; no payment due until FDA approval; vials for regulatory submission provided at no cost.
- Agreement provides second BCG source alongside Serum Institute's rBCG; rBCG remains available to eligible patients under FDA Expanded Access Program.

## SEC filing metadata
- accession: 0001193125-26-229153
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-05-18T21:20:47+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312526229153/0001193125-26-229153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312526229153/d75270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-229153
- JSON: https://secwatch.observer/filing/0001193125-26-229153.json
- Plain text: https://secwatch.observer/filing/0001193125-26-229153.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. entered into Exclusive Development and Supply Agreement with Japan BCG Laboratory valued at No payment due prior to FDA approval; minimum 2 batches per year after approval (effective 2026-05-14).
  - Action: entry
  - Agreement: supply
  - Counterparty: Japan BCG Laboratory
  - Value: No payment due prior to FDA approval; minimum 2 batches per year after approval
  - Effective: 2026-05-14
  source text: On May 14, 2026, ImmunityBio, Inc., a Delaware corporation (“ImmunityBio” or the “Company”), entered into an exclusive development and supply agreement (the “Agreement”) with Japan BCG Laboratory, a Japanese corporation (“JBL”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312526229153/0001193125-26-229153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.